788 related articles for article (PubMed ID: 32360300)
21. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.
Wang Y; Wang Y; Chen Y; Qin Q
J Med Virol; 2020 Jun; 92(6):568-576. PubMed ID: 32134116
[TBL] [Abstract][Full Text] [Related]
22. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
23. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
24. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
25. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
26. Effects of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) on the nervous system. What can we expect from SARS -CoV-2?
Monroy-Gómez J; Torres-Fernández O
Biomedica; 2020 Oct; 40(Supl. 2):173-179. PubMed ID: 33152201
[TBL] [Abstract][Full Text] [Related]
27. Coronavirus Disease 2019: Coronaviruses and Blood Safety.
Chang L; Yan Y; Wang L
Transfus Med Rev; 2020 Apr; 34(2):75-80. PubMed ID: 32107119
[TBL] [Abstract][Full Text] [Related]
28. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review.
Liya G; Yuguang W; Jian L; Huaiping Y; Xue H; Jianwei H; Jiaju M; Youran L; Chen M; Yiqing J
APMIS; 2020 Jun; 128(6):423-432. PubMed ID: 32363707
[TBL] [Abstract][Full Text] [Related]
29. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
30. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Wang M; Cao R; Zhang L; Yang X; Liu J; Xu M; Shi Z; Hu Z; Zhong W; Xiao G
Cell Res; 2020 Mar; 30(3):269-271. PubMed ID: 32020029
[No Abstract] [Full Text] [Related]
31. Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.
Xu P; Sun GD; Li ZZ
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5797-5809. PubMed ID: 32495918
[TBL] [Abstract][Full Text] [Related]
32. Natural and Nature-Derived Products Targeting Human Coronaviruses.
Vougogiannopoulou K; Corona A; Tramontano E; Alexis MN; Skaltsounis AL
Molecules; 2021 Jan; 26(2):. PubMed ID: 33467029
[TBL] [Abstract][Full Text] [Related]
33. Antiviral and Immunomodulatory Effects of Phytochemicals from Honey against COVID-19: Potential Mechanisms of Action and Future Directions.
Al-Hatamleh MAI; Hatmal MM; Sattar K; Ahmad S; Mustafa MZ; Bittencourt MC; Mohamud R
Molecules; 2020 Oct; 25(21):. PubMed ID: 33138197
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Li G; De Clercq E
Nat Rev Drug Discov; 2020 Mar; 19(3):149-150. PubMed ID: 32127666
[No Abstract] [Full Text] [Related]
35. A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic.
Gulati A; Pomeranz C; Qamar Z; Thomas S; Frisch D; George G; Summer R; DeSimone J; Sundaram B
Am J Med Sci; 2020 Jul; 360(1):5-34. PubMed ID: 32620220
[TBL] [Abstract][Full Text] [Related]
36. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
37. A comparative overview of COVID-19, MERS and SARS: Review article.
Liu J; Xie W; Wang Y; Xiong Y; Chen S; Han J; Wu Q
Int J Surg; 2020 Sep; 81():1-8. PubMed ID: 32730205
[TBL] [Abstract][Full Text] [Related]
38. [Biological Product Development Strategies for Prevention and Treatment of Coronavirus Disease 2019].
Yan CX; Li J; Shen X; Luo L; Li Y; Li MY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 51(2):139-145. PubMed ID: 32220178
[TBL] [Abstract][Full Text] [Related]
39. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
40. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
